The results showed that the expression levels of both E2F8 and MYBL2 were upregulated in female cancers compared to adjacent tissues, such as breast cancer (BRCA), ovarian cancer (OV), and cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC). Here, E2F8 is linked to ovarian cancer.